

North Central Cancer Treatment Group

N027D A Phase I Study of CCI-779 and Temozolomide in Combination with Radiation
Therapy in Glioblastoma Multiforme

Status Change – November 19, 2007

NOTICE OF STATUS CHANGE

This study is re-opening at dose level 1 (50 mg CCI-779) for another 3 patients effective
Monday, November 19, 2007.

Please retain this notice with the protocol.